Daniel Faga sold $1.1M of ANAB
President, CEO at ANAPTYSBIO, INC. 17,679 shares at an average of $61.61, traded Mar 27, 2026, filed Mar 27, 2026.
Score components
- +25RoleCEO
- +25Trade size$1.1M at market
- 0Share of holdings soldSold 3.4% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001673528-26-000007, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 25, 2026 | AGrant or award Common Stock | +34,300 | - | - | 513,644 | Mar 27, 2026 |
| Mar 27, 2026 | SOpen-market sale Common Stock | -510 | $56.61 | $29k | 513,134 | Mar 27, 2026 |
| Mar 27, 2026 | SOpen-market sale Common Stock | -2,570 | $57.91 | $149k | 510,564 | Mar 27, 2026 |
| Mar 27, 2026 | SOpen-market sale Common Stock | -3,662 | $58.62 | $215k | 506,902 | Mar 27, 2026 |
| Mar 27, 2026 | SOpen-market sale Common Stock | -490 | $59.62 | $29k | 506,412 | Mar 27, 2026 |
| Mar 27, 2026 | SOpen-market sale Common Stock | -550 | $60.63 | $33k | 505,862 | Mar 27, 2026 |
| Mar 27, 2026 | SOpen-market sale Common Stock | -1,012 | $62.15 | $63k | 504,850 | Mar 27, 2026 |
| Mar 27, 2026 | SOpen-market sale Common Stock | -2,592 | $63.35 | $164k | 502,258 | Mar 27, 2026 |
| Mar 27, 2026 | SOpen-market sale Common Stock | -3,155 | $64.19 | $203k | 499,103 | Mar 27, 2026 |
| Mar 27, 2026 | SOpen-market sale Common Stock | -3,038 | $65.20 | $198k | 496,065 | Mar 27, 2026 |
| Mar 27, 2026 | SOpen-market sale Common Stock | -100 | $65.99 | $6,599 | 495,965 | Mar 27, 2026 |
Related signals
Other insiders at ANAPTYSBIO, INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | ANAPTYSBIO, INC | Hollings Renton director | $249k 5,000 shares | -31% | |
| 9Weak | ANAPTYSBIO, INC | Eric J Loumeau CHIEF LEGAL OFFICER | $540k 10,000 shares | -44% | |
| 53Moderate | ANAPTYSBIO, INC | Magda Marquet director | $531k 11,000 shares | -53% | |
| 30Weak | ANAPTYSBIO, INC | Eric J Loumeau CHIEF LEGAL OFFICER | $99k 2,210 shares | -15% | |
| 37Weak | ANAPTYSBIO, INC | Dennis Mulroy CHIEF FINANCIAL OFFICER | $112k 2,515 shares | -10% | |
| 45Moderate | ANAPTYSBIO, INC | Daniel Faga President, CEO | $639k 14,281 shares | -3% | |
| 26Weak | ANAPTYSBIO, INC | Paul F. Lizzul Chief Medical Officer | $163k 3,650 shares | -8% | |
| 32Weak | ANAPTYSBIO, INC | Eric J Loumeau CHIEF LEGAL OFFICER | $439k 9,639 shares | -51% | |
| 31Weak | ANAPTYSBIO, INC | Dennis Mulroy CHIEF FINANCIAL OFFICER | $86k 1,908 shares | -10% | |
| 41Moderate | ANAPTYSBIO, INC | Daniel Faga President, CEO | $415k 9,202 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.